Vitamin C Pharmacokinetics in Critically Ill Patients

A Randomized Trial of Four IV Regimens


      Early high-dose IV vitamin C is being investigated as adjuvant therapy in patients who are critically ill, but the optimal dose and infusion method are unclear. The primary aim of this study was to describe the dose-plasma concentration relationship and safety of four different dosing regimens.


      This was a four-group randomized pharmacokinetic trial. Patients who were critically ill with multiple organ dysfunction were randomized to receive 2 or 10 g/d vitamin C as a twice daily bolus infusion or continuous infusion for 48 h. End points were plasma vitamin C concentrations during 96 h, 12-h urine excretion of vitamin C, and oxalate excretion and base excess. A population pharmacokinetic model was developed using NONMEM.


      Twenty patients were included. A two-compartment pharmacokinetic model with creatinine clearance and weight as independent covariates described all four regimens best. With 2 g/d bolus, plasma vitamin C concentrations at 1 h were 29 to 50 mg/L and trough concentrations were 5.6 to 16 mg/L. With 2 g/d continuous, steady-state concentrations were 7 to 37 mg/L at 48 h. With 10 g/d bolus, 1-h concentrations were 186 to 244 mg/L and trough concentrations were 14 to 55 mg/L. With 10 g/d continuous, steady-state concentrations were 40 to 295 mg/L at 48 h. Oxalate excretion and base excess were increased in the 10 g/d dose. Forty-eight hours after discontinuation, plasma concentrations declined to hypovitaminosis levels in 15% of patients.


      The 2 g/d dose was associated with normal plasma concentrations, and the 10 g/d dose was associated with supranormal plasma concentrations, increased oxalate excretion, and metabolic alkalosis. Sustained therapy is needed to prevent hypovitaminosis.

      Trial Registry; No.: NCT02455180; URL:

      Key Words


      ΔBE (change of the arterial blood base excess from baseline), IQR (interquartile range)
      To read this article in full you will need to make a payment


      Subscribe to CHEST
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Carr A.C.
        • Maggini S.
        Vitamin C and immune function.
        Nutrients. 2017; 9
        • Carr A.C.
        • Shaw G.M.
        • Fowler A.A.
        • Natarajan R.
        Ascorbate-dependent vasopressor synthesis: a rationale for vitamin C administration in severe sepsis and septic shock?.
        Crit Care. 2015; 19: 418
        • Padayatty S.J.
        • Doppman J.L.
        • Chang R.
        • et al.
        Human adrenal glands secrete vitamin C in response to adrenocorticotrophic hormone.
        Am J Clin Nutr. 2007; 86: 145-149
        • Jenkins J.S.
        The effect of ascorbic acid on adrenal steroid synthesis in vitro.
        Endocrinology. 1962; 70: 267-271
        • Levenson S.M.
        • Green R.W.
        Ascorbic acid, riboflavin, thiamin, and nicotinic acid in relation to severe injury, hemorrhage, and infection in the human.
        Ann Surg. 1946; 124: 840-856
        • Long C.L.
        • Maull K.I.
        • Krishnan R.S.
        • et al.
        Ascorbic acid dynamics in the seriously ill and injured.
        J Surg Res. 2003; 109: 144-148
        • Schorah C.J.
        • Downing C.
        • Piripitsi A.
        • et al.
        Total vitamin C, ascorbic acid, and dehydroascorbic acid concentrations in plasma of critically ill patients.
        Am J Clin Nutr. 1996; 63: 760-765
        • Carr A.C.
        • Rosengrave P.C.
        • Bayer S.
        • Chambers S.
        • Mehrtens J.
        • Shaw G.M.
        Hypovitaminosis C and vitamin C deficiency in critically ill patients despite recommended enteral and parenteral intakes.
        Crit Care. 2017; 21: 300
        • Marik P.E.
        • Hooper M.H.
        Doctor-your septic patients have scurvy!.
        Crit Care. 2018; 22: 23
        • Oudemans-van Straaten H.M.
        • Man A.
        • de Waard M.C.
        Vitamin C revisited.
        Crit Care. 2014; 18: 460
        • Jackson T.S.
        • Xu A.
        • Vita J.A.
        • Keaney J.F.
        Ascorbate prevents the interaction of superoxide and nitric oxide only at very high physiological concentrations.
        Circ Res. 1998; 83: 916-922
        • Levine M.
        • Padayatty S.J.
        • Espey M.G.
        Vitamin C: a concentration-function approach yields pharmacology and therapeutic discoveries.
        Adv Nutr. 2011; 2: 78-88
        • van Zanten A.R.
        • Sztark F.
        • Kaisers U.X.
        • et al.
        High-protein enteral nutrition enriched with immune-modulating nutrients vs standard high-protein enteral nutrition and nosocomial infections in the ICU: a randomized clinical trial.
        JAMA. 2014; 312: 514-524
        • Fowler A.A.
        • Syed A.A.
        • Knowlson S.
        • et al.
        Phase I safety trial of intravenous ascorbic acid in patients with severe sepsis.
        J Transl Med. 2014; 12: 32
        • Zabet M.H.
        • Mohammadi M.
        • Ramezani M.
        • Khalili H.
        Effect of high-dose ascorbic acid on vasopressor’s requirement in septic shock.
        J Res Pharm Pract. 2016; 5: 94-100
        • Marik P.E.
        • Khangoora V.
        • Rivera R.
        • Hooper M.H.
        • Catravas J.
        Hydrocortisone, vitamin-c, and thiamine for the treatment of severe sepsis and septic shock: a retrospective before-after study.
        Chest. 2017; 151: 1229-1238
        • Oudemans-van Straaten H.M.
        • Elbers P.W.G.
        • Spoelstra-de Man A.M.
        How to give vitamin C a cautious but fair chance in severe sepsis.
        Chest. 2017; 151: 1199-1200
        • Robitaille L.
        • Mamer O.A.
        • Miller W.H.
        • et al.
        Oxalic acid excretion after intravenous ascorbic acid administration.
        Metabolism. 2009; 58: 263-269
        • Lamarche J.
        • Nair R.
        • Peguero A.
        • Courville C.
        Vitamin C-induced oxalate nephropathy.
        Int J Nephrol. 2011; 2011: 146927
        • Berger M.M.
        • Oudemans-van Straaten H.M.
        Vitamin C supplementation in the critically ill patient.
        Curr Opin Clin Nutr Metab Care. 2015; 18: 193-201
        • Vincent J.L.
        • Moreno R.
        • Takala J.
        • et al.
        The SOFA (Sepsis-related Organ Failure Assessment) score to describe organ dysfunction/failure. On behalf of the Working Group on Sepsis-Related Problems of the European Society of Intensive Care Medicine.
        Intensive Care Med. 1996; 22: 707-710
        • Levine M.
        • Rumsey S.C.
        • Daruwala R.
        • Park J.B.
        • Wang Y.
        Criteria and recommendations for vitamin C intake.
        JAMA. 1999; 281: 1415-1423
        • Asplin J.R.
        Hyperoxaluric calcium nephrolithiasis.
        Endocrinol Metab Clin North Am. 2002; 31: 927-949
        • Hoppe B.
        An update on primary hyperoxaluria.
        Nat Rev Nephrol. 2012; 8: 467-475
        • Wilson J.X.
        Mechanism of action of vitamin C in sepsis: ascorbate modulates redox signaling in endothelium.
        Biofactors. 2009; 35: 5-13
        • May J.M.
        • Qu Z.C.
        Ascorbic acid prevents increased endothelial permeability caused by oxidized low density lipoprotein.
        Free Radic Res. 2010; 44: 1359-1368
        • Padayatty S.J.
        • Levine M.
        Vitamin C: the known and the unknown and Goldilocks.
        Oral Dis. 2016; 22: 463-493
        • Udy A.
        • Roberts J.A.
        • Boots R.J.
        • Lipman J.
        You only find what you look for: the importance of high creatinine clearance in the critically ill.
        Anaesth Intensive Care. 2009; 37: 11-13
        • Daudon M.
        • Letavernier E.
        • Frochot V.
        • Haymann J.P.
        • Bazin D.
        • Jungers P.
        Respective influence of calcium and oxalate urine concentration on the formation of calcium oxalate monohydrate or dihydrate crystals.
        Comptes Rendus Chim. 2016; 19: 1504-1513
        • Stephenson C.M.
        • Levin R.D.
        • Spector T.
        • Lis C.G.
        Phase I clinical trial to evaluate the safety, tolerability, and pharmacokinetics of high-dose intravenous ascorbic acid in patients with advanced cancer.
        Cancer Chemother Pharmacol. 2013; 72: 139-146
        • Hoffer L.J.
        • Levine M.
        • Assouline S.
        • et al.
        Phase I clinical trial of i.v. ascorbic acid in advanced malignancy.
        Ann Oncol. 2008; 19: 1969-1974
        • Riordan H.D.
        • Casciari J.J.
        • González M.J.
        • et al.
        A pilot clinical study of continuous intravenous ascorbate in terminal cancer patients.
        P R Health Sci J. 2005; 24: 269-276
        • Tanaka H.
        • Matsuda T.
        • Miyagantani Y.
        • Yukioka T.
        • Matsuda H.
        • Shimazaki S.
        Reduction of resuscitation fluid volumes in severely burned patients using ascorbic acid administration: a randomized, prospective study.
        Arch Surg. 2000; 135: 326-331
        • Lamas G.A.
        • Goertz C.
        • Boineau R.
        • et al.
        Effect of disodium EDTA chelation regimen on cardiovascular events in patients with previous myocardial infarction: the TACT randomized trial.
        JAMA. 2013; 309: 1241-1250
        • Kellum J.A.
        Determinants of blood pH in health and disease.
        Crit Care. 2000; 4: 6-14
        • de Grooth H.J.
        • Spoelstra-de Man A.M.
        • de Waard M.C.
        • Oudemans-van Straaten H.M.
        Plasma vitamin C in critically ill patients is related to organ dysfunction and mortality.
        Clin Nutr. 2014; 33 ([abstract]): S2